Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Running, not enrolling

Conditions studied: Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration

In brief

ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).

Key facts

Study ID

NCT04645212

Run by

Adverum Biotechnologies, Inc.

People needed

23

Starts

2020-12-14

Expected to finish

2030-06-26

Last updated by the study team

2026-02-10

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants who received a single dose of ADVM-022 at any dose in the OPTIC study
• Willing and able to provide informed consent

You may not qualify if…

• None

Where it is running

• Adverum Clinical Site — Bakersfield, California, United States
• Adverum Clinical Site — Beverly Hills, California, United States
• Adverum Clinical Site — Lakewood, Colorado, United States
• Adverum Clinical Site — Deerfield Beach, Florida, United States
• Adverum Clinical Site — Reno, Nevada, United States
• Adverum Clinical Site — Philadelphia, Pennsylvania, United States
• Adverum Clinical Site — Nashville, Tennessee, United States
• Adverum Clinical Site — Bellaire, Texas, United States
• Adverum Clinical Site — The Woodlands, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.